IL10 and Hypercholesterolemia: In the current study, we demonstrate inhibitory effects of exogenous IL-10 systemic administration on pain behaviors and skin inflammatory cell aggregation without affecting IGT, IFG, hypercholesterolemia, and hyperinsulinemia.